Diversifying the Global Heparin Supply Chain: Reintroduction of Bovine Heparin in the United States?
The global supply chain for bovine and porcine heparin and regulatory considerations are examined.
Tina S. Morris, PhD
Advertisement
Tina S. Morris, PhD, is vice president of Biologics & Biotechnology at United States Pharmacopeia (USP)
Articles by Tina S. Morris, PhD
A General Chapter on mAbs will be published in USP-NF as biologics increase their role in healthcare.
USP optimizes identification tests and impurities procedures.
USP promotes horizontal standards for biologics' quality attributes.
USP workshop participants support new methods to safeguard heparin products but desire international harmonization. This article contains bonus online-exclusive material.
USP's Stage 2 heparin monograph revisions address identification, potency, and impurities.
Advertisement
Latest Updated Articles
USP Further Strengthens Quality Standards for HeparinPublished: September 2nd 2012 | Updated:
Inside USP: International Dialogue on Biologics StandardsPublished: August 2nd 2011 | Updated:
Inside USP: Characterization of Heparin ProductsPublished: October 2nd 2009 | Updated:
Inside USP: Heparin Monographs Further RevisedPublished: March 2nd 2009 | Updated:
- USP Publishes Monoclonal Antibody Guidelines
Published: March 2nd 2015 | Updated:
Diversifying the Global Heparin Supply Chain: Reintroduction of Bovine Heparin in the United States?Published: November 2nd 2015 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Lilly Launches UK Trial of Weight-Loss Drug as US Price Drops
2
Live Cell High-Content Imaging is Driving Drug Discovery
3
Batch Certification for New Manufacturing Technologies: The Qualified Person Role in a Digital Environment
4
FAQ: Pharmaceutical Outsourcing Trends and Innovations
5
